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Abstract
There are four opportunities for HIV prevention: before exposure, at the moment of exposure,
immediately after exposure, and as secondary prevention focused on infected subjects. Until
recently, most resources have been directed toward behavioral strategies aimed at preventing
exposure entirely. Recognizing that these strategies are not enough to contain the epidemic,
investigators are turning their attention to post-exposure prevention opportunities. There is
increasing focus on the use of ART–either systemic or topical (microbicides)–to prevent infection
at the moment of exposure. Likewise, there is growing evidence that ART treatment of infected
people could serve as prevention as well. A number of ongoing clinical trials will shed some light
on the potential of these approaches. Above all, prevention of HIV requires decision-makers to
focus resources on strategies that are most effective. Finally, treatment of HIV and prevention of
HIV must be considered and deployed together.
Introduction
The 2007 UNAIDS report estimated that for every one per-
son who receives antiretroviral treatment, 4–6 other peo-
ple acquire HIV [1]. Yet, as has been recently noted [2],
HIV prevention programs and initiatives have made only
modest progress, and only in some communities. Further-
more, where there have been gains, they have not always
been sustainable. HIV prevention can only succeed under
the following conditions: i) all the available strategies are
used in combination as "highly active prevention" [3]; ii)
the menu of options are driven by scientific results and
not ideology; iii) affected communities work together
with organizations committed to prevention; iv) we con-
tinue use our growing knowledge of prevention–biologi-
cal, structural and behavioral–to move past the social,
economic, and other constraints we face today. Given the
often limited prevention resources, we must focus on
strategies that work [2]. In this article we review the docu-
mented successes and focus on recent data that is likely to
shape near-term HIV prevention strategies.
Prevention opportunities
There are four separate and discrete opportunities for HIV
prevention: before exposure to HIV, at the moment of
exposure, immediately after exposure, and among people
who are HIV infected [4] (Figure 1).
HIV prevention before exposure
Behavioral interventions directed at those who are not
infected with HIV must educate people about prevention,
encourage access to services such as treatment for sexually
transmitted infections or drug abuse, delay onset of first
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intercourse, increase condom use, and reduce the number
of sexual partners and/or sharing of syringes and needles.
Interventions can be deployed at the level of the individ-
ual, couple, family, peer group or network, institution, or
community [3] (Table 1). Voluntary counseling and test-
ing, a cornerstone of any HIV prevention strategy, can be
applied at each of these levels: to individuals, to couples
(as in Rwanda and Zambia), with entire families (as in
Uganda), with peer groups (Thailand), and with entire
communities (as in Project Accept).
Abstinence, be faithful, and condoms (ABC) has been the
key message of the global HIV prevention effort, but polit-
ical and religious influences have resulted in greater focus
on abstinence only, despite the clear evidence that com-
prehensive approaches are far more effective [5]. As Col-
lins and colleagues summarized,
It is time to scrap the ABCs and elevate the debate on
HIV prevention beyond the incessant controversies
over individual interventions. Small scale, isolated
programs, however effective, will not bring the AIDS
epidemic under control. To lower HIV incidence, espe-
cially in high transmission areas, policy makers,
donors, and advocates need to demand national pre-
vention efforts that re tailored to their epidemics,
bring quality interventions to scale, and address envi-
ronmental factors in vulnerability. That is why today's
most commonly cited acronym for HIV prevention–
"ABC"–falls severely short of what is needed to reduce
HIV transmission. ABC infantilizes prevention, over-
simplifying what should be an ongoing, strategic
approach to reducing incidence [6].
Barriers before exposure
Among the behavior change strategies for prevention of
HIV is the use of mechanical barriers during sexual inter-
course. The benefits of male condoms have been thor-
oughly documented [7], but the drawback is that these
devices need to be used properly and nearly 100% of the
time. According to a Cochrane review, when used prop-
erly, condom effectiveness is around 85% [8]. As a result
of prevention education efforts, a recent survey shows that
young woman in sub-Saharan Africa report increased con-
dom by their male partners [9]. Likewise, female condoms
have been shown to be an effective barrier against trans-
mission of STIs–including HIV–but they have gained little
popularity since their introduction [10].
In 2007, a study was conducted on the use of diaphragms
to prevent HIV acquisition [11]. Because the endocervix is
so rich in cells receptive to HIV [12], researchers had rea-
son to believe that a diaphragm would prevent HIV infec-
tion; however, this trial failed to demonstrate
protection[11]. The study results could be due to HIV
infection outside the cervix, because adherence was poor,
or because concomitant condom usage in both arms of
the study limited the ability to detect a benefit from the
diaphragm [11].
HIV Prevention opportunities, adapted from [4] Figure 1
HIV Prevention opportunities, adapted from4[4].
Table 1: A multilevel approach to behavioural strategies for HIV prevention with HIV counselling and testing as an example. 
Examples Applied to HIV counselling and testing
Individual Education; drug-related or sexual risk reduction 
counselling; skills building; prevention case 
management
HIV testing and counselling for individuals35
Couple Couples counselling HIV counselling and testing for couples35–38
Family Family-based counselling programmes Home-based family HIV counselling and testing39
Peer group/network Peer education; diffusion of innovation; network-
based strategies
Voluntary counselling and testing for all network 
members
Institution (eg, school, workplace, prisons) Institution-based programmes Services for voluntary counselling and testing 
available within workplaces and other institutional 
settings40
Community Mass media; social marketing; community 
mobilisation
Community-based voluntary counselling and 
testing (eg, Project Accept);41,42 Mobilisation 
and media to promote HIV counselling and testing
Adapted from [3].Journal of the International AIDS Society 2008, 11:4 http://www.jiasociety.org/content/11/1/4
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More recently, male circumcision has been studied as a
possible means for preventing HIV transmission. Circum-
cision essentially erects a permanent barrier against HIV
through removal of the foreskin. The mucosal foreskin
glans of the penis is rich in cells receptive to HIV infection
[12]. Powerful observational data suggested that circum-
cised men were much less likely to acquire HIV, implying
the glans is the main site of HIV acquisition in men. Three
randomized controlled trials demonstrated a minimum
of 60% reduction in HIV acquisition [13-15]. Conse-
quently, circumcision has been sought for high-risk sub-
jects, but the logistical challenges of providing enough
procedures to make an immediate impact are daunting.
Many infants born in resource-constrained countries lack
access to safe circumcisions, and there has been a distinct
lack of political will or patience to institute safe neonatal
circumcision worldwide.
Other sexually transmitted diseases: a 
reappraisal
Classical STDs amplify the transmission of HIV by
increasing the genital tract viral burden (infectiousness)
and increasing susceptibility to HIV [16]. Overwhelming
epidemiologic evidence links classical STDs and HIV [17],
especially STDs that are more ubiquitous (e.g. HSV-2, tri-
chomonas), produce lifelong infection (HSV-2), and/or
produce ulcers (HSV-2, syphilis). Recognizing that STDs
play a critical role in transmission, commitment to their
treatment for the prevention of HIV is essential. Unfortu-
nately, the results of clinical trials using treatment of STDs
for prevention have been disappointing [18].
To some extent, this is not surprising. STD treatment can
only prove effective if just the right person is treated for
just the right STD with effective antibiotics for the right
period of time. Most recently, daily suppressive treatment
of HSV-2 in people with established HSV-2 infection
failed to reduce HIV acquisition [19,20]. However, a sub-
stantial number of subjects developed genital ulcer, and it
seems unlikely that acyclovir, the antibiotic administered,
reduced the subclinical inflammation that is likely key to
HIV transmission. A trial to determine whether suppres-
sion of HSV-2 in HIV-infected subjects can decrease sexual
transmission of HIV-1 within a discordant couples is in
progress [21].
Still, the disappointing results of these trials should not
deliver the wrong message. First, the treatment of STDs is
critically important on its own merits [22]. Second, peo-
ple with STDs are much more likely to have unrecognized
HIV [23], including incident infection [24]. Third, people
with STDs who remain HIV negative have demonstrated
HIV risk behaviors that demand emergent prevention
efforts. HIV and classical STDs represent one, not two
problems, and the merging of these (currently) separate
disciplines is critical to reducing the incidence of both.
HIV prevention at the time of exposure: biology 
beyond barriers
If an HIV negative person has unprotected sexual exposure
to an HIV positive person, transmission is possible. The
transmission event is determined by the infectiousness of
the "index case" and the susceptibility of "the host"
[25](Figure 2). This topic has been extensively reviewed in
the scientific literature [4]. The viral inoculum [26] and
phenotype [27] play a critical role in transmission proba-
bility. The higher the concentration of the virus in the
blood, the greater the probability of the transmission
event [26,28]. In addition, the transmitted virus has
unique properties: a single HIV variant launches sexually
transmitted HIV infection 80% of the time [27], and the
transmitted virus is generally capable of using the CCR5
receptor [27]. Conversely, polymorphisms and deletions
in the CCR5 receptor reduce the probability of HIV acqui-
sition [29]. In addition, the transmitted virus appears to
be less well defended against antibody attack (i.e. a
reduced glycan shield) [30].
Studies with HIV transmission in macaques show that
both cell free (Miller C et al. JV 2005) and cell associated
[31] HIV can be transmitted through vaginal exposure. In
the presence of an ulcer, infection of mucosal cells and
spread to lymph nodes is inordinately fast [31]. In
humans, the probability of HIV transmission is likely
amplified by sexually transmitted diseases that cause ulcer
[16,32].
Beyond mechanical barriers, there are only two ways to
prevent HIV infection at the moment of exposure: a cred-
ible host defense and/or antiviral therapy.
Development of a protective HIV vaccine
The limits of vaccine development have been extensively
discussed [25,33]. Three immune options have received
Infectiousness and susceptibility, adapted from [16] Figure 2
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the greatest attention: innate immunity, humoral immu-
nity (antibodies) and/or cell-mediated immunity (cyto-
toxic lymphocytes) [34].
Antibodies have the capacity to block the attachment of
HIV to receptive cells, or to neutralize HIV [35]. Indeed, a
group of monoclonal antibodies which neutralize HIV-1
have been identified and described [36]. These antibodies
have been used successfully in passive immunity experi-
ments to protect infant rhesus macaques from peroral
infection [37]. However, this type of neutralizing antibod-
ies is not generally formed in vivo, perhaps because they
are similar to autoantibodies that could harm the host
[38]. HIV infection gradually leads to the formation of
other antibodies [39] which form weeks or months after
infection and after the creation of HIV mutants that uni-
formly escape the action of these antibodies [40]. Most of
these antibodies will not neutralize heterologous viruses.
However, a small number of hosts will develop broad
neutralizing antibodies long after initial infection. The
precise molecular mechanisms by which neutralizing
broad antibodies limit HIV replication are not under-
stood. Parenthetically, antibodies directed against HIV
form too late in primary infection to explain reduction in
viral burden [39].
The time between exposure to HIV, infection, and viral
replication is very short (Figure 3) [39]. Even if a vaccine
that evokes protective antibodies is developed, it will be a
challenge for an anamnestic (memory) antibody response
to evolve sufficiently enough to prevent transmission.
Protection from HIV infection might require antibody
generation at the mucosal surface (IgG or IgA) [41], and
no mucosal vaccines have been developed. In addition,
acute HIV infection compromises the B cell immune
response required for antibody formation. About 30% of
patients with acute HIV infection have Rhematoid factor
detected, indicating disturbed function of B cells [39]. To
date, one vaccine designed to stimulate antibodies has
been tested, and no protection from infection was
observed, although this vaccine did not generate systemic
or mucosal neutralizing antibodies [42].
Given the difficulty in developing an antibody-based vac-
cine, investigators gravitated toward development of vac-
cines that stimulate cell-mediated immunity [34]. It has
been demonstrated that i) animals with lymphocyte
depletion cannot control viral replication; ii) some vac-
cines that stimulate a cell-mediated immune response
limit the peak of viremia and transiently decrease the viral
burden at "set-point" in macaques; and iii) improve ani-
mal survival [43]. While there is virtually no evidence that
a T-cell based vaccine can prevent infection, it has long
been argued that a reduced peak and set point HIV burden
could prevent secondary transmission of HIV, and benefit
the health and survival of the host.
A recent trial of a vaccine (Merck V520) that stimulated
HIV responsive T cells failed to prevent HIV acquisition
[44]. However, the vaccine also failed to reduce viral load
at set point. Furthermore, more infections were observed
in the group that received the vaccine than in the control
group, but the reason for this phenomenon is not known
[45]. Another ongoing trial that tests HIV proteins deliv-
ered in a canary pox virus vector and boosted with gp120
will be completed in 2009.
ART for prevention
The use of antimicrobial agents to prevent the spread of
infections has a long, broad and very successful history. It
is surprising that to date, ART has not been more widely
adapted as a prevention tool. ART is safe, available,
becoming more affordable, and subject to structural mod-
ification(s) that might improve drug usage for public
health purposes. While it is true that cost, toxicity, lack of
adherence and viral drug resistance challenge the utility of
the approach, it seems inevitable that ART will play a
larger role in the HIV epidemic in the near future, but
until recently this area of research has lacked a sense of
urgency and adequate funding.
There are three ways ART could be employed: as pre-expo-
sure prophylaxis (PreP), as post-exposure prophylaxis
(PEP), and as prevention of secondary transmission from
an infected person through suppression of viral concen-
tration in the genital tract [46].
Pre-exposure Prophylaxis (PreP)
Studies with animals have strongly suggested that antiret-
roviral drugs delivered topically (i.e. "microbicides") or
systemically can prevent the transmission of HIV-1 [47-
49]. A series of studies from the US Centers for Disease
Control and Prevention used multiple rectal mucosal viral
HIV-1 Transmission Event, adapted from [25] Figure 3
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challenge on macaques who were given daily antiretrovi-
ral agents [50,51]. Tenofovir delayed SHIVSF162P3 infec-
tion, but after repeated exposure infection was prevented
in only 1 of 4 animals studied [51]. However, high-dose
tenofovir and emtricitabine given subcutaneously pro-
tected 6 of 6 macaques from infection [50].
Based on this animal data, trials of oral pre-exposure
prophylaxis for uninfected high-risk individuals are now
under way in Peru, Ecuador, Thailand, Botswana, and the
United States. These trials use either tenofovir or a combi-
nation of tenofovir and emtricitabine [52] (Table 2).
Results will emerge as early as 2010. It should be noted,
however, that all of these trials offer prolonged (i.e. one
year or more) daily dosing, interventions which are
expensive and potentially toxic. It seems likely that pre-
vention benefits will ultimately be realized with a briefer
combination of pre- and post-exposure prophylaxis (see
below), particularly since the most recent macaque stud-
ies suggest that optimally timed doses of PreP and a single
dose of PEP are sufficient for protection.
Antiretroviral therapy can also be delivered topically, via
agents known as microbicides, a subject which has been
extensively reviewed [53]. While the early days of micro-
bicide research focused on drugs other than ART (e.g.
detergents, surface active agents), a variety of more tar-
geted biological products (antibodies and ART) are now
being studied [53]. There are studies being conducted on
antiviral agents including NNRTIs (s-DABO, TMC-120, U-
781, and MIV-150), and the NRTI tenofovir is about to
enter a phase 3 clinical efficacy trial.
Particularly exciting is the emergence of new, slow-release
vaginal devices that might permit infrequent dosing of
effective compounds [53]. One potential problem with
topical ART is low-level, systemic absorption, which could
promote antiviral resistance; however, in a completed
PReP safety trial no women who acquired HIV developed
mutations associated with tenofovir resistance [54].
Postexposure prophylaxis (PEP)
The only prevention treatment option after unprotected
HIV exposure is emergent use of antiretroviral agents [55].
Prophylaxis following occupational exposure to HIV is
considered standard of care in the United States [56] and
in most other countries [52]. This protocol was developed
primarily from studies in macaques [57] and a single case
control study of health care workers with needle stick
exposures [58]. In the latter study, thirty-three healthcare
workers who sero-converted following percutaneous
exposure were compared with control subjects selected
from six hundred and seventy-nine individuals who did
not seroconvert after postexposure prophylaxis. Zidovu-
dine (in a few cases, other antiretrovirals) given to individ-
uals after percutaneous exposure to HIV led to an 81% risk
reduction (CI, 48% to 94%) in HIV seroconversion.
Conducting randomized, controlled, clinical trials of pos-
texposure prophylaxis to prevent the occupational or sex-
ual transmission of HIV in humans are not feasible
because of the inefficient transmission of HIV per sexual
exposure, and the prohibitive cost of enrolling the very
large number of subjects that would be needed to estab-
lish benefit. Current CDC guidelines recommend the use
of 3 antiretroviral agents for 28 days following high-risk
Table 2: Current and Proposed Pre-Exposure Prophylaxis Trials, October 2007 Study (Sponsor) Study and Agent(s) (Dose) Population 
(Target N) Sites [52].
Study (sponsor) Study and Agent(s) (Dose) Population (Target N) Sites
US CDC-NCHSTP-4323 Phase II daily TDF or daily oral 
placebo
MSM ages 18 to 60 (400) US (anticipated completion 2009)
US CDC-NCHSTP-4370 Phase II/III daily TDF or daily oral 
placebo
IDU ages 20 to 60 (2,000) Thailand 
(anticipated completion 2008)
CDC-NCHSTP-4940; BOTUSA 
MB06
Phase III daily Truvada or daily oral 
placebo
Men and women ages 18 to 29 
(1,200)
Botswana 
(anticipated completion 2010)
iPrEX (NIAID/BMGF) Phase III daily Truvada or daily oral 
placebo
MSM ages 18 and up (3,000) Peru, Ecuador, Brazil, Thailand, 
South Africa, US 
(anticipated completion 2011)
FHI (USAID) ) Phase III daily Truvada or daily 
oral placebo
High-risk women ages 18 to 35 
(3,900)
Kenya, Malawi, South Africa, 
Tanzania, Zimbabwe (study 
planned, no anticipated completion 
date yet)
Partners Study (BMGF) Phase III daily TDF, daily Truvada, 
or daily oral Placebo
Discordant heterosexual couples 
ages 18 to 60 (4,000)
Uganda, Kenya 
(study planned, no anticipated 
completion date yet)
VOICE/MTN 003 (NIAID) Phase IIB safety and effectiveness 
of daily tenofovir gel (1%) or 
placebo gel, or daily TDF (300 mg), 
Truvada, or oral placebo
Nonpregnant premenopausal 
women ages 18 to 35 
(2,400 oral, 1,600 gel)
South Africa, Zambia, Malawi, 
Uganda, Zimbabwe (study planned, 
no anticipated completion date 
yet)Journal of the International AIDS Society 2008, 11:4 http://www.jiasociety.org/content/11/1/4
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sexual exposure to a known or suspected HIV-infected
partner [56]. Based on animal experiments it seems clear
that prophylaxis should be administered urgently. In fail-
ures reported in a PEP registry delayed administration was
a critical risk factor [59].
Prevention for positives
Prevention for positives is only possible if a person knows
his or her HIV status. Voluntary counseling and testing
strategies (VCT), a cornerstone of HIV prevention, has
generally been seen as a first defense against the spread of
HIV disease, with the idea that a negative serological test,
combined with prevention information, would inspire
harm reduction [60-62]. Recognizing the critical role of
knowledge of status, the US CDC and many other govern-
ments and organizations have recently moved to "opt-out
testing" [63]. Others have championed the implementa-
tion of universal routinized testing [64].
One key and unresolved issue in preventing the sexual
transmission of HIV is identifying the population most
critical to the spread of the virus. Given the close relation-
ship between viral load and transmission probability, one
could assume that people with acute HIV and late infec-
tion (untreated) might be of greatest importance [65].
Indeed, in the only empiric study to address this issue a,
substantial number of transmission events could be
linked to index cases in precisely these stages of disease
[26]. But a recent and compelling mathematical modeling
exercise argued that subjects with unrecognized estab-
lished infection with moderate viral loads in their blood
(100,000 copies) are most critical [66], a finding which
underscores the importance of knowledge of status.
A substantial number of couples are "discordant" (one
partner is HIV-infected and the other is not). Recent mas-
sive household screening studies [21,67] have demon-
strated that 49% of couples screened can be expected to be
discordant, with some regional differences. Ongoing
transmission within discordant couples occurs at a rate of
about 8–11% per year, even in the face of counseling [68].
Thus the considerable danger of HIV transmission within
untested discordant couples should not be underesti-
mated [67,69].
These observations emphasize the importance of timely
HIV detection and the need to develop effective coun-
seling strategies to reduce the likelihood of secondary HIV
transmission from people who know they are HIV
infected. Studies on secondary transmission have raised
the concern that ART treatment could actually increase the
spread of HIV as a result of improved general health and
increased libido after starting ART treatment [60]. Even
more worrisome, this increase in secondary transmission
would include resistant strains of the virus through
patients who discontinue or fail therapy [60].
Recent studies have highlighted these concerns. William-
son et al. [70] found that HIV-infected men who have sex
with men in the UK (and who knew their serostatus) had
higher risk behaviors (including unprotected anal inter-
course and intercourse) with partners of unknown or dis-
cordant serostatus than men who were negative or did not
know their serostatus. Eisele et al. [71] found ongoing risk
behaviors among men and women awaiting ART in Cape
Town, South Africa; correlates of risk included failure to
disclose serostatus and misconceptions about the rela-
tionship between ART and HIV transmission.
ART for suppression of HIV
When used properly, ART can be expected to suppress HIV
in the blood and the male genital tract [72]; suppression
of HIV in the female genital tract appears to be less rapid
and reliable [73]. However, STDs can increase shedding of
HIV even in men [74] and women [75] receiving ART.
While episodic viral shedding is easily documented, the
risk of a transmission event during shedding is unknown.
There are three lines of evidence to suggest that ART
reduces infectiousness of treated patients: retrospective
analysis, prospective observational studies and ecological
data. In two retrospective studies, HIV transmission was
greatly reduced when the index cases in couples were
offered therapy [76,77]. Two prospective observational
studies had similar findings. In one study, of 1034 dis-
cordant couples in Zambia and Rwanda, the index part-
ners in 248 couples were receiving ART [78]. Among the
42 partners in this cohort who acquired HIV since 2003,
only 2 had partners receiving ART. A similar prospective
observational study of Ugandan patients initiating ART
reported a 98% reduction in the estimated risk of HIV
transmission following the start of ART [79].
Retrospective and observational studies are susceptible to
the effects of unexpected modifiers, including unmeasured
sexual behavior(s) and condom use. In addition, the peri-
ods of observation generally cannot determine long term
benefit or detect transmission of resistance viruses (see
below). Perhaps most importantly, the studies only include
index subjects who require ART for low CD4 counts or
advanced HIV disease, whereas ART for prevention might
wisely be employed at a much higher CD4 count, especially
in people at greatest risk for transmitting HIV.
Several ecologic studies of the preventative benefit of ART
have been completed. In a large closed cohort of homo-
sexual men in San Francisco, California, a 60% reduction
in anticipated cases of HIV was attributed to availability ofJournal of the International AIDS Society 2008, 11:4 http://www.jiasociety.org/content/11/1/4
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ART for infected sexual partners [80]. A study from Taiwan
showed a 53% reduction in the expected cases of HIV fol-
lowing the free provision of ART in 1997 [81]. More
recently, a study in British Columbia, Canada suggested
that up to 50% of expected incident HIV cases were
averted by ART [82].
However, ecological prevention benefits of ART have not
been universal. No reduction in incident HIV infections
among men who have sex with men in San Francisco was
observed despite widespread availability of ART [83], and
increases in HIV incidence were found among homosex-
ual men attending sexually transmitted disease clinics in
Amsterdam, the Netherlands from 1991 to 2001 [84]
regardless of treatment roll-out. Ecologic studies are
greatly limited by an "ecologic fallacy": the inability to
relate the patients who receive therapy to the actual inci-
dence or prevalence of HIV in the community. In addi-
tion, the accuracy of HIV prevalence and incidence data in
these many of these settings is unknown.
A randomized, controlled trial is underway to try to define
the impact of ART on HIV transmission. HPTN 052 is
designed to compare the effectiveness of two different
treatment strategies to prevent the sexual transmission of
HIV among 1750 serodiscordant couples [85]. HIV-
infected partners with a CD4 count between 350–550
cells/mm3 are randomly assigned to initiate ART at enroll-
ment or to delay ART until their CD4 T-cell count falls
below 250 cells/mm3 or they develop an AIDS-defining
illness. The results should detect a 35% reduction in HIV
transmission to sexual partners due to ART treatment of
HIV-infected subjects. In addition, this study compares
the benefits of early versus delayed ART (ACTG 5245), a
critical question if ART is going to be used more broadly
as a public health tool.
Rational selection of antiviral agents for 
prophylaxis or prevention
The number and choice of antiviral agents (whether sys-
temic or topical) is vital to the success of any of the inter-
ventions discussed. The choice of ART regimen must also
take into account the risk of HIV-resistant variants and the
pharmacology of antiviral agents. The prevalence of de
novo resistance in individuals with incident HIV infection
differs greatly by country and region [86] but should be
taken into account in selecting ART prophylactic regi-
mens. Furthermore, resistance in the genital tract can be
unique and sustained [87].
Recent findings on the pharmacology of antiretrovirals in
the genital tract suggest that certain antiretroviral agents
may be preferable for the prevention of HIV following sex-
ual exposure (Figure 4). Lamivudine, emtricitabine, zido-
vudine, tenofovir and maraviroc concentrations in the
female genital tract were higher than blood plasma, and
lopinavir and atazanavir achieved low to moderate genital
tract concentrations [88]. Efavirenz achieved female geni-
tal secretion concentrations <1% blood plasma. In addi-
tion, many antiretrovirals are detected in genital
secretions within 1–2 hours after the first dose of ART.
These results should be used to guide selection of agents
for HIV PreP and PEP, and perhaps secondary prevention
as well.
Ease of therapy is also an important consideration in
choosing an ART regimen for non-occupational postexpo-
sure prophylaxis. Two case-controlled studies of non-
occupational postexposure prophylaxis following high
risk sexual exposures were conducted using tenofovir DF
and lamivudine in 44 subjects and the combination of
tenofovir DF and emtricitabine in an additional 68 sub-
jects. Subjects in both studies with tenofovir-based dual
regimens had higher completion rates of a 28-day postex-
posure regimen than historical controls taking 2- or 3-
drug regimens containing zidovudine (P < 0.0001) [89].
Dropout rates during non-occupational postexposure
prophylaxis treatment are high [90,91], particularly in
cases of sexual assault [92-95]. Although the reasons for
discontinuation of therapy may include reassessment of
risk exposure and/or intolerable side effects, the evidence
of increased adherence with simpler regimens should not
be ignored. Finally, it seems clear that health care workers
need more education about PEP [96].
ART and public health reality
There are many mathematical models of the effects of ART
on the epidemic, both ART used as PreP [97] or provided
to people with established infection [46,98,99]. These
models are greatly limited by their assumptions, and none
has been subjected to experimental investigation. The big-
gest questions include adherence, degree of benefit, and
population volume served. In other words, are enough
people at risk of or infected with the disease receiving the
right ART at the right times and for long enough to make
a difference? In addition, the public health benefits of ART
for people with HIV are up for debate, since ART cannot
be readily offered to people with acute HIV infection and
people with very advanced disease, since neither group is
aware of their status during maximal contagion.
What if?
We are at a critical juncture for HIV prevention research
[2]. It is clear that we cannot simply treat all individuals
who become infected. We do not have the tools to make
an HIV vaccine [34], and there is no "magic bullet" solu-
tion on the horizon. Currently there is intense interest in
multi-faceted approaches, but it seems unlikely that
behavioral interventions alone will prove sufficient to
change the course of the epidemic [3]. The tool currentlyJournal of the International AIDS Society 2008, 11:4 http://www.jiasociety.org/content/11/1/4
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most readily available is ART, and ART–as PreP, PEP or
treatment–will likely play an increasing role in HIV pre-
vention. Indeed, it is possible that the indications for ART
treatment will evolve to consider the public health bene-
fit(s) with the same intensity and urgency as the individ-
ual therapeutic benefit(s).
Perhaps the most immediate issue facing us is what to do
with the things that work. For example, barrier methods
(condoms and circumcision) are clearly effective, but they
have by no means reached their full prevention potential.
The difficulty in rolling out circumcision, especially in
countries most greatly affected by HIV, has been a source
of great frustration. Similarly, how do we prepare properly
for the broad application of ART, should the trials under-
way demonstrate the anticipated success? And how do we
deal with methods that do not work? How do we develop
a strategy that recognizes the importance of STDs in HIV
transmission without the expectation that treatment of
STDs per se will alter the course of the epidemic? How do
we demonstrate a commitment to vaccine development,
short of conducting large-scale clinical trials unlikely to
succeed?
These issues can only be properly addressed if the research
community works well and creatively with public health
leaders and agencies, and this has not always been the case
[100]. Given the potential trajectory of HIV prevention,
now is the time to address these questions. We have mas-
tered some fundamental tools of HIV prevention, and
many more are on the way. In the meantime, we must
implement all the tools at our disposal, monitor their suc-
cesses, and prevent the transmission of HIV.
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